In vitro activity of biapenem against beta-lactamase producing Enterobacteriaceae
- PMID: 7889951
- DOI: 10.1007/BF02111342
In vitro activity of biapenem against beta-lactamase producing Enterobacteriaceae
Abstract
The activity of biapenem was compared with that of imipenem and cefotaxime against 108 strains of beta-lactamase producing Enterobacteriaceae. Biapenem and imipenem were very active, inhibiting 90% of the strains at a concentration of 0.5 microgram/ml. Both carbapenems were very active against plasmidic beta-lactamase producers, with MIC90s below 1 microgram/ml. However, the MIC90 of biapenem for cephalosporinase producers was 1 microgram/ml. Against strains producing extended-spectrum beta-lactamases, biapenem exhibited better activity against TEM-type producers (MIC90 0.25 microgram/ml) than against SHV-type producers (MIC90 0.5 microgram/ml). Overall, the in vitro antibacterial activity of biapenem is similar to that of imipenem.
Similar articles
-
Comparative in-vitro activity of biapenem against enterobacteria with beta-lactamase-mediated antibiotic resistance.J Antimicrob Chemother. 1994 Mar;33(3):453-64. doi: 10.1093/jac/33.3.453. J Antimicrob Chemother. 1994. PMID: 8040111
-
[in vitro activity of carbapenems against Enterobacteriaceae and Pseudomonas aeruginosa hyperproducers of group 1 chromosomal beta-lactamases].Enferm Infecc Microbiol Clin. 1997 Sep;15 Suppl 1:20-6. Enferm Infecc Microbiol Clin. 1997. PMID: 9410065 Spanish.
-
In vitro activity of three carbapenem antibiotics. Comparative studies with biapenem (L-627), imipenem, and meropenem against aerobic pathogens isolated worldwide.Diagn Microbiol Infect Dis. 1993 Nov-Dec;17(4):299-305. doi: 10.1016/0732-8893(93)90039-a. Diagn Microbiol Infect Dis. 1993. PMID: 8112045
-
Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.Drugs. 2018 Jan;78(1):65-98. doi: 10.1007/s40265-017-0851-9. Drugs. 2018. PMID: 29230684 Review.
-
Phenotypic detection of extended-spectrum beta-lactamase production in Enterobacteriaceae: review and bench guide.Clin Microbiol Infect. 2008 Jan;14 Suppl 1:90-103. doi: 10.1111/j.1469-0691.2007.01846.x. Clin Microbiol Infect. 2008. PMID: 18154532 Review.
Cited by
-
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Biapenem in Healthy Adult Subjects.Antimicrob Agents Chemother. 2023 May 1;65(5):e02612-20. doi: 10.1128/AAC.02612-20. Epub 2021 Mar 8. Antimicrob Agents Chemother. 2023. PMID: 33685898 Free PMC article.
-
Population pharmacokinetics, dosing optimization and clinical outcomes of biapenem in patients with sepsis.Front Pharmacol. 2024 May 10;15:1388150. doi: 10.3389/fphar.2024.1388150. eCollection 2024. Front Pharmacol. 2024. PMID: 38799155 Free PMC article.
-
Biapenem.Drugs. 2002;62(15):2221-34; discussion 2235. doi: 10.2165/00003495-200262150-00005. Drugs. 2002. PMID: 12381221 Review.
-
Real-world Biapenem vs. Meropenem in the treatment of severe community-acquired pneumonia in children: A propensity score matching analysis.Front Pediatr. 2022 Nov 21;10:1047595. doi: 10.3389/fped.2022.1047595. eCollection 2022. Front Pediatr. 2022. PMID: 36479282 Free PMC article.